Abstract | BACKGROUND & AIMS: METHODS: Patients were randomized to receive MLN0002 2.0 mg/kg (n = 65), MLN0002 0.5 mg/kg (n = 62), or placebo (n = 58) by intravenous infusion on days 1 and 29. The primary efficacy end point was clinical response (>or=70-point decrement in the Crohn's Disease Activity Index [CDAI] score) on day 57. Secondary end points were the proportions of patients with clinical remission (CDAI score <or=150) and with an enhanced clinical response (>or=100-point decrement in CDAI). Human anti-human antibody levels were measured. RESULTS: Clinical response rates at day 57 were 53%, 49%, and 41% in the MLN0002 2.0 mg/kg, MLN0002 0.5 mg/kg, and placebo groups. Clinical remission rates at day 57 were 37%, 30%, and 21%, respectively (P = .04 for the 2.0 mg/kg vs placebo comparison). At day 57, 12% and 34% of patients in the 2.0- and 0.5-mg/kg groups had clinically significant human anti-human antibody levels (titers > 1:125). There was one infusion-related hypersensitivity reaction. The most common serious adverse event was worsening of Crohn's disease. CONCLUSIONS: This phase 2 study was suggestive of a dose-dependent beneficial effect of MLN0002 therapy on clinical remission. MLN0002 was well tolerated in patients with active Crohn's disease.
|
Authors | Brian G Feagan, Gordon R Greenberg, Gary Wild, Richard N Fedorak, Pierre Paré, John W D McDonald, Albert Cohen, Alain Bitton, Jeffrey Baker, Réjean Dubé, Steven B Landau, Margaret K Vandervoort, Asit Parikh |
Journal | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
(Clin Gastroenterol Hepatol)
Vol. 6
Issue 12
Pg. 1370-7
(Dec 2008)
ISSN: 1542-7714 [Electronic] United States |
PMID | 18829392
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Integrins
- Placebos
- integrin alpha4beta7
- vedolizumab
|
Topics |
- Adult
- Anti-Inflammatory Agents
(administration & dosage, adverse effects, therapeutic use)
- Antibodies, Monoclonal
(administration & dosage, adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Crohn Disease
(drug therapy)
- Double-Blind Method
- Female
- Humans
- Infusions, Intravenous
- Integrins
(antagonists & inhibitors)
- Male
- Middle Aged
- Placebos
(administration & dosage)
- Severity of Illness Index
- Treatment Outcome
|